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REFEREE REPORTS
Referee #1:
In this manuscript, Dr. Lim and his colleagues reported a new link between the deubiquitinase USP9X and AMOTL2, through which USP9X regulated YAP phosphorylation, localization, transcriptional activity and its function in cell proliferation. Mechanistically, USP9X promoted YAP activity through associating with and deubiquitinating AMOTL2 and subsequent reduction of AMOTL2-LATS2 interaction and LATS2 kinase activity to YAP. This work is potentially significant as it uncovered a new mechanism of ubiquitinaon/deubiquitination of AMOTL2 in the regulation of the Hippo signaling pathway. However, I do have a few concerns on the role of USP9X uncovered by this study:
1. The authors claimed mono-ubiquitination of AMOTL2 is the major ubiquitinated species for its inhibitory effect on YAP activity. To my knowledge, I think the presented data is not enough to support the author's claim. I would like to see the ubiquitinated pattern of AMOTL2 by mutant ubiquitin (K free) parallel to Fig 4A and its role on YAP parallel to Fig 6E. 2. USP9X is required for maximal YAP activity from knock-down assays in sparse condition (Fig  2A-C) . Could USP9X overexpression in densely cultured cells reactivate YAP (such as phosphorylation, localization) as in sparsely cultured cells? Could USP9X expression decrease by cell density increasing? Based on Fig 2C , the protein level of USP9X is increased from sparse to dense conditions (compare the control panels in Fig 2C) . If not, please discuss the possible reasons. 3. As USP9X is recovered as a YAP-associating protein (Supplementary table 1) and USP9X formed an immunoprecipitation complex with AMOTL2 (Fig 4E-F) . The authors didn't provide any data to mention the interaction between YAP and USP9X. Please give me an explanation. 4. Ubiquitination of AMOTL2 seems to be important for the interactions between AMOTL2 and YAP, andAMOTL2 and LATS2. Does AMOTL2-mediated regulation of USP9X on LATS2 activity require YAP's association with AMOTL2?
Referee #2:
The authors identify a novel ubiquitylation mechanism for regulating AMOT -like proteins. They show that USP9X is a DUB for AMOTL2 using a variety of biochemical and cell culture approaches. What is lacking is any in vivo genetic evidence for an important role for USP9x. Nevertheless, if this mechanism proves to be important in vivo, this paper will be cited widely and will be an important contribution to the field. We would like to thank the reviewers for insightful and productive suggestions. Accordingly, we have performed the suggested experiments.
In addition to reviewers' comments, we also have added new data in Appendix Fig S3, which shows that USP9X IP-complex can de-ubiquitinate AMOTL2 in vitro. We believe that this result further strengthens our conclusion that AMOTL2 is a substrate of USP9X. Below, we describe our new experiments and responses to the reviewers' comments.
In this manuscript, Dr. Lim and his colleagues reported a new link between the deubiquitinase USP9X and AMOTL2, through which USP9X regulated YAP phosphorylation, localization, transcriptional activity and its function in cell proliferation. Mechanistically, USP9X promoted YAP activity through associating with and deubiquitinating AMOTL2 and subsequent reduction of AMOTL2-LATS2 interaction and LATS2 kinase activity to YAP. This work is potentially significant as it uncovered a new mechanism of ubiquitination/deubiquitination of AMOTL2 in the regulation of the Hippo signaling pathway. However, I do have a few concerns on the role of USP9X uncovered by this study: This is a very insightful comment and we thank the reviewer for pointing out this issue. To address the reviewer's concern, we have performed new experiments as suggested. First, we performed ubiquitination assay for AMOTL2 using either WT Ub or K0 mutant Ub (K free). We found that both WT and K0 Ub are equally incorporated into AMOTL2. This new result is provided in the newly revised Fig 5A. Second, we performed LATS2 kinase assay using either WT Ub or K0 Ub. As expected, cotransfection of AMOTL2 increased LATS2 kinase activity, and addition of WT Ub further increased LATS2 activity. Importantly, K0 Ub also showed comparably increased LATS2 activity to WT Ub. This result is provided in Appendix Fig S4. Taken together, experiments using K0 Ub indicate that AMOTL2 mono-ubiquitination is functionally sufficient.
2. USP9X is required for maximal YAP activity from knock-down assays in sparse condition (Fig  2A-C) . Could USP9X overexpression in densely cultured cells reactivate YAP (such as phosphorylation, localization) as in sparsely cultured cells? Could USP9X expression decrease by cell density increasing? Based on Fig 2C , the protein level of USP9X is increased from sparse to dense conditions (compare the control panels in Fig 2C) . If not, please discuss the possible reasons. Fig 2F) , increases YAP target gene levels (Appendix Fig  S1A) , and decreases YAP S127 phosphorylation (Fig 3B) .
We also took the advantage of recently described CRISPR-SAM system [1] . This system utilizes nickase-deficient Cas9 fused to transcriptional co-activators. Introduction of sgRNA targets Cas9 to target genes. We obtained three sgRNAs that successfully increased USP9X level in RPE cells. Using them, we demonstrate that USP9X over-expression increases nuclear YAP when seen by cell fractionation (Fig 2G) , increases YAP target gene levels (Appendix Fig  S1B) , and decreases YAP S127 phosphorylation (Fig 3C) . Importantly, we confirm that knockdown of USP9X by siRNA reduces YAP target gene levels back, excluding off-target effects of sgRNAs (Appendix Fig S1C) . Taken together with immunostaining results, these data clearly show that gain of USP9X function can re-activate YAP in densely growing cells. 1C and 3A) show some increment of USP9X in dense conditions, we never observed such phenomenon in RPE cells. We do not clearly understand the reason underlying such cell type dependency yet. However, whatever the mechanism is, we believe that regulation of USP9X at the protein level is not a general mechanism. We rather speculate that USP9X activity (also potentially protein level) might be regulated by LATS-mediated phosphorylation. This conjecture is based on the fact that LATS2-USP9X interaction increases in okadaic acid treated cells [2] , in which LATS2 is activated, and that USP9X contains putative LATS target sequence (Appendix Fig S5) . We have described these in the discussion section.
We also consider potential regulation of USP9X by cell-density as an important issue. Although Western blot results obtained from MCF10A cells (Figs
3. As USP9X is recovered as a YAP-associating protein (Supplementary table 1) and USP9X formed an immunoprecipitation complex with AMOTL2 (Fig 4E-F) . The authors didn't provide any data to mention the interaction between YAP and USP9X. Please give me an explanation.
We thank the reviewer for the insightful comment. As the reviewer pointed out, we first identified USP9X as a YAP immunoprecipitant. We also confirmed their interaction with over-expressed USP9X and YAP in 293T cells as well as with endogenous proteins in RPE and MCF10A cells (Now provided in Fig EV5) . However, we believe that the YAP immunoprecipitated complex surely included both direct and indirect interacting proteins. After we started to investigate the functional role of USP9X in the Hippo signaling, we reached the conclusion that USP9X regulates Hippo signaling through de-ubiquitination of AMOTL2.
Currently, we think that YAP-USP9X interacts indirectly through YAP-LATS interaction. Supporting this view, Couzens et al. reported LATS2-USP9X interaction in okadaic acid treated cells [2] , wherein LATS2 is activated. Importantly, our purification was also performed in detached cells, which activates LATS kinase. In addition, as we described in response to comment 2, USP9X has putative LATS2 target sequence (Appendix Fig S5) . Taken together, we hypothesize that following LATS activation, both LATS-YAP and LATS-USP9X complexes are formed, likely leading to indirect interaction between YAP and USP9X. Of course, this hypothesis requires additional experimental validation and is an important future subject of research. We have described these in the discussion section.
4. Ubiquitination of AMOTL2 seems to be important for the interactions between AMOTL2 and YAP, and AMOTL2 and LATS2. Does AMOTL2-mediated regulation of USP9X on LATS2 activity require YAP's association with AMOTL2?
As the reviewer has pointed out, understanding the mechanistic relationship between AMOTL2-YAP interaction and other AMOTL2 modifications is a very important mechanistic question. To address this question, we generated AMOTL2 Y213A mutant (mutation in the PPXY motif), that fails to interact with YAP. Very interestingly, AMOTL2 Y213A mutant also failed to be ubiquitinated (Now provided in Fig 6E) . Therefore, AMOTL2-YAP interaction is required for either recruitment of hypothetical E3 ligase or repulsion of USP9X. AMOTL2 is regulated by multiple mechanisms including AMOTL2-YAP interaction [3, 4] , phosphorylation by LATS [5, 6] and mono-ubiquitination (Our study). Intriguingly, these regulatory mechanisms seem to cooperate in positive feed-forward manner. In the future, a systematic study using multiple AMOTL2 mutants would allow us to dissect the precise mechanism of AMOTL2 regulation. In addition to Fig 6E, we have described this in the discussion section, too. We are grateful for the reviewer's comments.
The authors identify a novel ubiquitylation mechanism for regulating AMOT -like proteins. They show that USP9X is a DUB for AMOTL2 using a variety of biochemical and cell culture approaches. What is lacking is any in vivo genetic evidence for an important role for USP9x. Nevertheless, if this mechanism proves to be important in vivo, this paper will be cited widely and will be an important contribution to the field.
In this manuscript, we identified AMOTL2 as a target of USP9X by using both cellular genetics and biochemical approaches. We completely agree with the reviewer's comment. While it is practically not suitable to perform in vivo mouse genetic experiments during the revision period, we have performed additional functional assays regarding the importance of AMOTL2 ubiquitination.
In our previous manuscript, we only showed that AMOTL2 knock-down decreased YAP S127 phosphorylation and increased YAP target gene expressions, and that only AMOTL2 WT (but not AMOTL2 K347/408R mutant) rescues this. We further expand this result by performing functional assays including 1) analysis of EMT markers by RT-qPCR, 2) transwell migration assay and 3) soft agar assay. These results are provided in Fig 7. 
